Reports
Sale
Major Depressive Disorder Market Size, Analysis, Forecast: By Product Type: Benzodiazepines, Antidepressant Drugs, SSRIs, SNRIs, Others; By Treatment Type: Medication, Psychotherapy, Brain Stimulation Therapies; By Diagnosis Tests; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Major Depressive Disorder Market Outlook
The major depressive disorder market size was valued at USD 6.1 billion in 2023, driven by the rising prevalence of major depressive disorder across the 8 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2024-2032, with the values likely to rise from USD 6.4 billion in 2024 to USD 9.6 billion by 2032.
Major Depressive Disorder Market Overview
Major depressive disorder (MDD) is characterized by persistently low and depressed mood along with a loss of interest in everyday activities. The incidence rate is rising in the younger population due to alcohol and drug abuse. According to the Mental Health America prevalence data of 2023, 16.39% of youth aged between 12-17 years suffered from at least one major depressive episode (MDE) in the previous year. The state prevalence of MDE in youth was reported to be 12.57% in New Jersey and 21.13% in Oregon.
Major depressive disorder is highly prevalent in women, owing to several factors such as hormonal differences, different psychosocial stressors, and childbirth effects. The average onset of this psychiatric disorder is estimated to be 40 years . The rising prevalence of mental illnesses is projected to boost the major depressive disorder market growth in the forecast period.
The market is witnessing steady growth supported by the surge in drug approvals by the health regulatory agencies. For instance, in October 2023, the United States Food and Drug Administration (FDA) approved gepirone ER, marketed as Exxua, to treat major depressive disorder (MDD). The medication developed by Fabre-Kramer Pharmaceuticals, Inc. (a United States pharmaceutical company) targets the serotonin 1A receptor, a key mood regulator. Exxua is the only drug that selectively stimulates the receptor without any adverse symptoms of weight gain or sexual dysfunction. The availability of such drugs in the market will positively influence the market landscape.
The major depressive disorder market demand is further bolstered by the rising geriatric population at a higher risk of developing mental disorders. The rising mental health campaigns and initiatives by the government to support patients suffering from clinical depression are also anticipated to accelerate the market growth in the forecast period.
Major Depressive Disorder Market Trends
| Key Trends | Description |
| Personalized Medicine | There is a growing demand for personalized or precision medicine in treating MDD, where treatments are customized based on individual genetic makeup, lifestyle, and response to past treatments. |
| Digital Therapeutics | There has been an emergence of digital therapeutics, including apps to track symptoms, and provide therapeutic activities. These tools are becoming an important part of the treatment regimen for MDD. |
| Combination Therapies | An increasing focus on combination therapies that use a mix of medications, psychotherapy, and lifestyle changes to treat MDD. |
| Next-Generation Antidepressants | The development of next-generation antidepressants that target new pathways and mechanisms of action beyond the traditional pathways. This includes drugs targeting the glutamatergic system and other novel approaches to treat MDD more effectively and with fewer side effects. |
Major Depressive Disorder Market Segmentation
Market Breakup by Product Type
- Benzodiazepines
- Antidepressant Drugs
- SSRIs
- SNRIs
- Others
The market for treating major depressive disorder (MDD) can be segmented by product type, including benzodiazepines, antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other medications. This market segment comprises the pharmacological options available for managing MDD.
Market Breakup by Treatment Type
- Medication
- Antidepressant Drugs
- Adjunctive Therapies
- Psychotherapy
- Cognitive Behavioral Therapy (CBT)
- Interpersonal Therapy (IPT)
- Other Therapeutic Approaches
- Brain Stimulation Therapies
- Electroconvulsive Therapy (ECT)
- Transcranial Magnetic Stimulation (TMS)
The major depressive disorder market report includes segmentation based on treatment types. It includes medication, psychotherapy, and brain stimulation therapies. Under medication, options include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). This market segment offers a range of interventions available for managing MDD, aligning with patients’ needs and preferences.
Market Breakup by Diagnosis Tests
- Psychological Assessments
- Blood Tests
- Imaging Technologies
- Laboratory Tests
- Other Diagnostic Tools
Based on diagnostic tests, the major depressive disorder market share includes psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools. This market segment shows the approaches to diagnosing MDD, which forms an essential part of effective treatment planning.
Market Breakup by Distribution Channel
- Pharmacies and Retail Stores
- Online Pharmacies
- Hospitals and Clinics
- Others
Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels. The diverse network of these channels helps in accommodating the diverse clinical needs of patients suffering from major depressive disorder.
Market Breakup by End User
- Hospitals and Clinics
- Mental Health Centres
- Ambulatory Surgical Centres (ASCs)
Major end users of the major depressive disorder market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs). Mental health centers provide mental health care, such as diagnosis and therapy to MDD patients.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America dominates the regional market, attributed to the high prevalence rates of major depressive disorder. Rapid technological advancements in the healthcare sector and the rise in the geriatric population base, which is more susceptible to develop the condition. Such factors are expected to further bolster the market growth in the region.
Major Depressive Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Lundbeck
- AbbVie
- Relmada Therapeutics
- Axsome Therapeutics
- Alkermes
- Intra-Cellular Therapies
- Allergan plc
- Pfizer Inc.
- Sanofi S.A.
- Johnson & Johnson
- Merck & Co.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- AstraZeneca Plc
- GSK plc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis Tests |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Major Depressive Disorder Market Report
- How has the major depressive disorder market performed so far and how is it anticipated to perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of major depressive disorder affect the market landscape?
- How does the rise in the geriatric population impact the major depressive disorder market size?
- What treatment type of major depressive disorder will dominate the market share?
- Which diagnostic method is expected to have a high market value in the coming years?
- Which product type will experience the highest demand in the market segment?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in major depressive disorder treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Major Depressive Disorder Market Overview – 8 Major Markets
3.1 Major Depressive Disorder Market Historical Value (2017-2023)
3.2 Major Depressive Disorder Market Forecast Value (2024-2032)
4 Major Depressive Disorder Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Major Depressive Disorder Epidemiology Analysis- 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.1 Germany Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.2 France Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.3 Italy Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.4 Spain Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.4 Japan Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.5 China Major Depressive Disorder Epidemiology Forecast (2017-2032)
7 Major Depressive Disorder Market Landscape*- 8 Major Markets
7.1 Major Depressive Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Major Depressive Disorder Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Treatment Type
8 Major Depressive Disorder Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Major Depressive Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Porter’s Five Forces Model
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Major Depressive Disorder Market Segmentation (2017-2032) - 8 Major Markets
11.1 Major Depressive Disorder Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Benzodiazepines
11.1.3 Antidepressant Drugs
11.1.4 SSRIs
11.1.5 SNRIs
11.1.6 Others
11.2 Major Depressive Disorder Market (2017-2032) by Treatment Type
11.2.1 Market Overview
11.2.2 Medication
11.2.2.1 Antidepressant Drugs
11.2.2.2 Adjunctive Therapies
11.2.3 Psychotherapy
11.2.3.1 Cognitive Behavioral Therapy (CBT)
11.2.3.2 Interpersonal Therapy (IPT)
11.2.3.3 Other Therapeutic Approaches
11.2.4 Brain Stimulation Therapies
11.2.4.1 Electroconvulsive Therapy (ECT)
11.2.4.2 Transcranial Magnetic Stimulation (TMS)
11.3 Major Depressive Disorder Market (2017-2032) by Diagnosis Tests
11.3.1 Market Overview
11.3.2 Psychological Assessments
11.3.3 Blood Tests
11.3.4 Imaging Technologies
11.3.5 Laboratory Tests
11.3.6 Other Diagnostic Tools
11.4 Major Depressive Disorder Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Pharmacies and Retail Stores
11.4.3 Online Pharmacies
11.4.4 Hospitals and Clinics
11.4.5 Others
11.5 Major Depressive Disorder Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals and Clinics
11.5.3 Mental Health Centres
11.5.4 Ambulatory Surgical Centres (ASCs)
11.6 Major Depressive Disorder Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 China
12 United States Major Depressive Disorder Market (2017-2032)
12.1 United States Major Depressive Disorder Market Historical Value (2017-2023)
12.2 United States Major Depressive Disorder Market Forecast Value (2024-2032)
12.3 United States Major Depressive Disorder Market (2017-2032) by Product Type
12.3.1 Market Overview
12.3.2 Benzodiazepines
12.3.3 Antidepressant Drugs
12.3.4 SSRIs
12.3.5 SNRIs
12.3.6 Others
12.4 Major Depressive Disorder Market (2017-2032) by Treatment Type
12.4.1 Market Overview
12.4.2 Medication
12.4.2.1 Antidepressant Drugs
12.4.2.2 Adjunctive Therapies
12.4.3 Psychotherapy
12.4.3.1 Cognitive Behavioral Therapy (CBT)
12.4.3.2 Interpersonal Therapy (IPT)
12.4.3.3 Other Therapeutic Approaches
12.4.4 Brain Stimulation Therapies
12.4.4.1 Electroconvulsive Therapy (ECT)
12.4.4.2 Transcranial Magnetic Stimulation (TMS)
13 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032)
13.1 EU-4 and United Kingdom Major Depressive Disorder Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Major Depressive Disorder Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032) by Product Type
13.3.1 Market Overview
13.3.2 Benzodiazepines
13.3.3 Antidepressant Drugs
13.3.4 SSRIs
13.3.5 SNRIs
13.3.6 Others
13.4 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032) by Treatment Type
13.4.1 Market Overview
13.4.2 Medication
13.4.2.1 Antidepressant Drugs
13.4.2.2 Adjunctive Therapies
13.4.3 Psychotherapy
13.4.3.1 Cognitive Behavioral Therapy (CBT)
13.4.3.2 Interpersonal Therapy (IPT)
13.4.3.3 Other Therapeutic Approaches
13.4.4 Brain Stimulation Therapies
13.4.4.1 Electroconvulsive Therapy (ECT)
13.4.4.2 Transcranial Magnetic Stimulation (TMS)
14 Japan Major Depressive Disorder Market (2017-2032)
14.1 Japan Major Depressive Disorder Market Historical Value (2017-2023)
14.2 Japan Major Depressive Disorder Market Forecast Value (2024-2032)
14.3 Japan Major Depressive Disorder Market (2017-2032) by Product Type
14.3.1 Market Overview
14.3.2 Benzodiazepines
14.3.3 Antidepressant Drugs
14.3.4 SSRIs
14.3.5 SNRIs
14.3.6 Others
14.4 Japan Major Depressive Disorder Market (2017-2032) by Treatment Type
14.4.1 Market Overview
14.4.2 Medication
14.4.2.1 Antidepressant Drugs
14.4.2.2 Adjunctive Therapies
14.4.3 Psychotherapy
14.4.3.1 Cognitive Behavioral Therapy (CBT)
14.4.3.2 Interpersonal Therapy (IPT)
14.4.3.3 Other Therapeutic Approaches
14.4.4 Brain Stimulation Therapies
14.4.4.1 Electroconvulsive Therapy (ECT)
14.4.4.2 Transcranial Magnetic Stimulation (TMS)
15 China Major Depressive Disorder Market (2017-2032)
15.1 China Major Depressive Disorder Market Historical Value (2017-2023)
15.2 China Major Depressive Disorder Market Forecast Value (2024-2032)
15.3 China Major Depressive Disorder Market (2017-2032) by Product Type
15.3.1 Market Overview
15.3.2 Benzodiazepines
15.3.3 Antidepressant Drugs
15.3.4 SSRIs
15.3.5 SNRIs
15.3.6 Others
15.4 China Major Depressive Disorder Market (2017-2032) by Treatment Type
15.4.1 Market Overview
15.4.2 Medication
15.4.2.1 Antidepressant Drugs
15.4.2.2 Adjunctive Therapies
15.4.3 Psychotherapy
15.4.3.1 Cognitive Behavioral Therapy (CBT)
15.4.3.2 Interpersonal Therapy (IPT)
15.4.3.3 Other Therapeutic Approaches
15.4.4 Brain Stimulation Therapies
15.4.4.1 Electroconvulsive Therapy (ECT)
15.4.4.2 Transcranial Magnetic Stimulation (TMS)
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Lundbeck
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 AbbVie
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Relmada Therapeutics
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Axsome Therapeutics
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Alkermes
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Intra-Cellular Therapies
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Allergan plc
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Pfizer Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Sanofi S.A.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Johnson & Johnson
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Merck & Co.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Eli Lilly and Company
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Takeda Pharmaceutical Company Limited
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 AstraZeneca Plc
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 GSK plc
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
23 Major Depressive Disorder Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 6.1 billion in 2023 driven by the rising prevalence of major depressive disorder across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.3% during the forecast period of 2024-2032, likely to reach a market value of USD 9.6 billion by 2032.
The market demand is driven by the rising geriatric population at a higher risk of developing mental disorders.
One of the significant market trends revolves around the surge in drug approvals by health regulatory agencies. For instance, in October 2023 , the United States Food and Drug Administration (FDA) approved Fabre-Kramer Pharmaceuticals, Inc.’s gepirone ER (marketed as Exxua) to treat major depressive disorder (MDD).
Based on the product type, the market is segmented into benzodiazepines, antidepressant drugs, SSRIs, SNRIs, and other medications.
Based on the treatment type, the market is segmented into medication, psychotherapy, and brain stimulation therapies. Medications include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).
Major end users of the market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs).
Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels.
Diagnostic tests available in the market include psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are Lundbeck, AbbVie, Relmada Therapeutics, Axsome Therapeutics, Alkermes, Intra-Cellular Therapies, Allergan plc, Pfizer Inc., Sanofi S.A., Johnson & Johnson, Merck & Co., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AstraZeneca Plc, and GSK plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER